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Abstract
The leading cause of death from gynecologic malignancies is epithelial ovarian cancer. These tumors are comprised of
a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to
regenerate tumors in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are
resistant to conventional cancer therapies and play essential roles in metastasis and tumor relapse. While
chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. It has been
hypothesized that cancer stem cells are at the root of this problem. Their ability to self-renew and proliferate is what
causes a large number of ovarian cancers to recur and not respond to normal chemotherapeutic treatments. Recent
evidence suggests that deregulation of stem cell pathways is a key factor in the onset and maintenance of
chemoresistance. Several key markers such as BMI1, FZD1, GGSK3b, NANOG, TWIST1, and OCT4 (POU5F1) are
hypothesized to play a central role in the development and differentiation of multiple cell lineages. Recent studies have
demonstrated that these markers is required for the carcinogenesis in several cancer types. The aim of this study was to
investigate the significance of CSC expression in chemoresistant and sensitive ovarian cancer cancer cell lines.
Through the analysis of gene expression in these cell lines, CSC markers could be identified. CSC mRNA expression
was detected by real-time quantitative PCR and by gel electrophoresis of PCR products in sensitive and resistant
ovarian cell lines. The objective of such an improved delineation is to develop targeted therapy for selective
elimination of cancer stem cells with minimal toxicity to normal stem cells. Our research indicates that there were
novel changes in gene expression in the chemoresistant cell lines, specifically involving GSK3b. Further research is
needed to gain better understanding of the role that these genes specifically play in cancer survival, metastasis, and
chemo resistance.
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1. Introduction:
Epithelial ovarian cancer is the result of the ovarian surface epithelium cells becoming malignant (Hennessy 2009).
Every year 220,000 women develop epithelial ovarian cancer worldwide. In the United States, it is considered to be the
gynecologic malignancy with the most fatalities (Seiden 2001). Pelvic pain, bloating, and frequent urination are among
the most common symptoms of the disease (Walker 2018). The symptoms are quite nonspecific, which causes
numerous cases to remain undiagnosed (Sun 2016). There are four main stages of this disease, and various substages.
In Stage IA, the tumor is limited to one ovary. The tumor is located in both ovaries in Stage IB. Stage IC is diagnosed
when the tumor is limited to one or two ovaries with signs such as capsule rupture, tumor on ovarian surface, and/or
malignant cells in ascites. Stage II of epithelial ovarian cancer is characterized by the spreading of the tumor to the
pelvis. The tumor spreads to the uterus and fallopian tubes in Stage IIA, and extends to the other pelvic tissues in Stage
IIB (Jayson 2014). Ovarian cancer tumors that are diagnosed between stages I and IIA generally have the most
promising survival rates, with approximately 80% of women living 5 years or more post-diagnosis (Burges 2011).
Pelvic extension with malignant cells in ascites occurs during Stage IIC. Stage III of ovarian cancer involves presence
of the tumor in one or both ovaries and shows microscopically confirmed peritoneal implants outside of the pelvis
leading to abdominal disease.
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Stage IIIA shows microscopic metastases beyond the pelvis, while Stage IIIB shows macroscopic peritoneal metastases
beyond the pelvis with 2cm or less. Peritoneal metastases beyond the pelvis with 2cm or greater are evident in Stage
IIIC. Finally, Stage IV tumors show signs of distant metastases to the liver. (Jayson 2014). At this late stage, less than
10% of patients live 5 years or more after diagnosis (Huang 2017).
Most of the women diagnosed with this disease are found to have stage III (Jayson 2014). In these cases, treatment
usually involves tumor debulking surgery, followed by a platinum-based chemotherapy regimen (Cortez 2017). While
treatment is often very successful, ovarian cancer still has a very high death rate. This is due to the late presentation of
symptoms. It is also due in part to the fact that women that are diagnosed with the advance disease or stage III will
often develop episodes of recurrent disease with a shorter disease-free interval, typically within 18 months of treatment.
(Jayson, 2014). The survival rate for women diagnosed with the advance disease is only 25% compared to those with
the early stage whose survival rate is typically 80-90%. Outcomes can be improved if the tumor is detected at an early
stage of development. Unfortunately, this disease does not produce any ovarian cancer-specific symptoms in the early
stages, which is why it is difficult to diagnose the disease early on (Colombo 2006). Recurrence arises when cell
populations evade the effects of chemotherapy. Non-proliferative, or quiescent, cancer cells are resistant to paclitaxel
and carboplatin. Although a general problem for all ovarian cancers, recurrence is variable among subtypes. The
majority (90%) of ovarian cancers develop in the epithelium with the highest rate of recurrence.
A subpopulation of tumor cells that have the capacity to differentiate, self-renew, and produce a tumor upon
implantation into an animal host are known as cancer stem cells (Yu 2012). Cancer stem cells are also commonly
referred to as tumor initiating cells (Parte 2018). It is hypothesized that cancer stem cells arise from mutated stem cells,
although studies have shown that mutated progenitor cells might be responsible (Jordan 2006). Recurrence of ovarian
cancer tumors post-treatment could be due to the presence of these cancer stem cell populations, as they are generally
chemoresistant (Beck 2013). These cells acquire resistance through a variety of mechanisms. Many platinum based
drugs induce tumor regression by causing DNA damage to the cancer cell. Cancer cells often have defective DNA
repair pathways. The rapid proliferation of these cells is often in S-phase, which is a vulnerable phase for DNA
damage. Due to the chemotherapy drugs, these cells are not able to repair from the DNA damage. However, studies
show that cancer stem cells have elevated levels of DNA repair. This provides an explanation as to potentially why they
become resistant. (Thomas 2014). Additionally, cancer stem cells have a slow proliferation rate. Because chemotherapy
drugs are designed to target rapidly dividing cells, the cancer stem cell population is often unaffected (Nunes 2018).
Because cancer stem cells prevent chemotherapy from completely eradicating tumors, various research projects have
focused on determining how cancer stem cells function on the epigenetic level. Specifically, the identification of cancer
stem cell markers could allow for cancer stem cell identification and improved ovarian cancer diagnostics (Paula 2017).
Previous studies have determined that CD133, CD44, CD117, and CD24 are ovarian cancer stem cell markers (BurgosOjeda 2012), however, many other ovarian cancer stem cell markers that could prove to be useful in the diagnosis and
treatment of the disease remain unidentified.
A consideration of the unique cellular and environmental features of chemoresistant ovarian cancer cells could shed
light on potential therapeutic improvements targets. The aim of this study was to analyze the gene expression changes
in chemoresistant and chemosensitive human cell lines of several cancer stem cell markers thought to play an important
role in ovarian cancer chemoresistance.
Our study revealed several gene expression changes, primarily involving the stem cell marker GSK3b. GSK3b plays a
role in apoptotic mechanisms and the regulation of oxidative stress. The inhibition of GSK3b expression is crucial in
maintaining the stability of Nrf2. Nrf2 prevents oxidative stress, which is a necessary measure in the maintenance of
healthy, undamaged cellular DNA. Over expression of GSK3b leads to uncontrolled oxidative stress, and therefore,
cancer stem cell proliferation (Mancinelli 2017). We hypothesize that understanding the molecular mechanisms
underlying this drug resistance is important for the development of effective therapies to improve ovarian cancer
patients' outcome.

2. Materials and Methods:
2.1 Materials
HOSE 6-3, a normal human ovarian surface epithelial cell line that has been immortalized by HPV E6/7 ORF (obtained
from Dr. S. W. Tsao, Cold Spring Harbor Laboratory, NY) cell line was used to study ovarian cancer proliferation. All
cell lines were maintained in MEM 10% fetal bovine serum. SYBR Green I fluorescent dye, reverse transcriptase and
RNase inhibitor was purchased from BiMake. BioRad supplied the cDNA conversion kit.
RNEasy, DNEasy obtained from Qiagen. Cisplatin and Carboplatin were purchased from Sigma. Primers were
supplied by Sigma Genosys. Cell counting kit-8 was purchased from Dojindo Molecular Technologies, Inc.
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2.2 Cell lines
Several human cell lines were used in this study. SKOV3 and CA-CRSPR were the chemoresistant cell lines, CAOV3
was the chemosensitive cell line, and HOSE was the control. SKOV3 and CAOV3 are human ovarian cancer cell lines
derived from ovarian epithelium. All cell lines were maintained in minimum essential medium-α supplemented with
10% FBS (Invitrogen) in the presence of 100 U/mL of penicillin and 100 μg/mL of streptomycin, and were incubated at
37°C with 5% CO2. The cultured cells were split every 2 to 3 days and maintained in an exponential growth phase. All
cell lines were purchased at ATCC. These cell lines have been routinely tested for Mycoplasma contamination in the
laboratory.
2.3 Pathway Analysis
DAVID, Ingenuity, gPROFILER are bioinformatics database is used to analyze large gene/protein lists and used to
study in order to gain biological meaning. Analysis was useful in gaining a better understanding of candidate genes
involved in chemoresistance in ovarian cancer. Once an uploaded gene list is obtained, analysis can be performed in
order to classify the genes based on different mechanisms and pathways that are good for our study. PubMed metaanalysis can be done with smaller gene lists of interest to gain information on chemoresistant mechanisms.
2.4 Cell Counting Kit-8
Cell Counting Kit-8 (CCK-8) is a colorimetric assays for the determination of cell viability in cell proliferation and
cytotoxicity assays. The water-soluble tetrazolium salt, WST-8, is reduced by dehydrogenase activities in cells to give a
yellow-color formazan dye, which is soluble in the tissue culture media. The amount of the formazan dye, generated by
the activities of dehydrogenases in cells, is directly proportional to the number of living cells. We used it to measure
cell proliferation where increased absorbance using a spectrophotometer correlates to increased cell death. The
BioTek800 plate reader was used to measure absorbance at 450 nm filter.
2.5 EarlyTox Live/Dead Assay
This live/dead assay kit utilizes two cell markers that fluoresce based on the integrity of a cells membrane. Calcein AM
was the marker used for live cells and ETHD-III for dead cells. Calcein AM permeates a live, intact cell membrane and
is there converted into its green fluorescent form, Calcein. The population of live cells was calculated based on the
intensity of this green fluorescence (emission 495-530 nm). ETHD-III was used as a dead-cell marker because is
impermeable to intact cell membranes and enters broken or compromised cell membranes where it binds to nucleic
acids and fluoresces red. The population of dead cells was calculated based on the intensity of this red fluorescence
(emission 530-645 nm). Fluorescence was measured using the SpectraMax microplate reader.
2.6 Primers
A variety of different primers were utilized in this study to test their expression in the aforementioned cell lines. Each
primer was used as a component of the qPCR master mix. The master mix contained a forward and reverse sequence of
each primer. The complete list of primers used in this experiment can be found in Figure 1.
2.7 DNA Extraction
DNA extraction is the process by which DNA is separated from proteins, membranes, and other cellular material
contained in the cell from which it is recovered (Elkins 2013).
We began our DNA extraction by pipetting 20 ul QIAGEN protease into a 1.5 microcentrifuge tube. 200 ul of the
sample and another 200 ul of the buffer were added to the tube and mixed by vortexing for 15 seconds. The tube was
incubated at 56C for 10 minutes. 200 ul of ethanol were added next and mixed by vortexing another 15 seconds. Next it
was centrifuged for a minute and the tube containing the filtrate was discarded. Buffer was added next and then
centrifuged for another minute. The previous step was repeated three times until the tube was incubated at room
temperature for a minute then centrifuged one last time at 8000 rpm. Incubating at room temperature before
centrifugation generally increases DNA yield.
2.8 PCR
Polymerase Chain Reaction (PCR) uses DNA polymerase to amplify a small DNA sample by synthesizing multiple
new copies (Garibyan 2013). DNA polymerase requires a primer to allow for the addition of the first nucleotide onto a
3‟-OH group. After the PCR reaction is completed, the DNA sample is amplified into billions of copies (“Polymerase
Chain Reaction” 2017). PCR products can be visualized through gel electrophoresis. Following DNA extraction,
SKOV3 and HOSE DNA were run through a PCR machine in order to amplify the sequences. Prior to PCR, the DNA
samples were mixed with certain primers. A PCR Master Mix was made for a total of 12 reactions. Two master mix
solutions were made up, one for each DNA type. The master mix contained SKOV3 or HOSE DNA, Master Mix
solution and distilled water.
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The DNA was inserted into PCR tubes. Each tube within the strip contained a forward primer and a reverse primer. The
primers used were ACT, SOX9, FDZ1, POU5F1 (OCT4), NOTCH3, SLUG, GSK3b and ZEB1. The PCR tubes were
ran in the PCR machine for DNA amplification. Finally, the PCR tubes were ran on a gel electrophoresis for
visualization. The PCR was performed following manufacturer‟s protocol.
ACT, forward, 5‟-TTGCAGCTCCTTCGTTGC-3‟; reverse, 5‟-GTGGTACGACCAGAGGCATAC-3‟; SOX9,
forward, 5‟-GACGCTGGGCAAGCTCT-3‟; reverse, 5‟-GTAATCCGGGTGGTCCTTCT-3‟; FDZ1, forward, 5‟CAGCAGTACAACGGCGAAC-3‟; reverse, 5‟-GTCCTCCTGATTCGTGTGGC-3‟; POU5F1 (OCT4), forward, 5‟AGTTGGCGTGGAGACTTTGC-3‟; reverse, 5‟-CAGGGCTTTCATGTCCTGG-3‟; NOTCH3, forward, 5‟GTGTGTGTCAATGGCTGGAC-3‟; reverse, 5‟-GTGACACAGGAGGCCAGTCT-3‟; SLUG, forward, 5‟CTGCGGCAAGGCGTTT-3‟; reverse, „5-CGTGTGAGTTCTAATGTGTCCTTGA-3‟; GSK3b, forward, 5‟GGAACTCCAACAAGGGAGCA-3‟; reverse, 5‟-TTCGGGGTCGGAAGACCTTA-3‟; ZEB1, forward, 5‟TTCACAGTGGAGAGAAGCCA-3‟; reverse, 5‟-GCCTGGTGATGCTGAAAGAG-3‟.
2.9 Gel Electrophoresis
Gel electrophoresis is a technique in nucleic acid biochemistry that involves the separation of molecules based on their
size (Chadalavada 2009). During this experiment, 1% agarose gels with ethidium bromide were used to separate DNA
in a 1x tris-acetate buffer. 10μl of the DNA (SKOV3 or HOSE) from the PCR tubes were mixed with 5μl of blue dye.
A total of 15μl was loaded into each well. Samples were run at 100V for approximately 45 minutes and visualized
using a UV-transilluminator with a camera.
2.10 cRNA Extraction
RNA extraction was performed following the IBI Scientific protocol. In short, first cell lysis was done to break up the
tissue pellet. The mixture was transferred to a collection tube with a filter column before being centrifuged at a speed of
1,000 x g. RNA binding was step two of the process, involving the addition of 70% ethanol and centrifugation at
16,000 x g using a new collection tube. The flow-through in the collection tube was discarded. Step three, wash, used
the Wash Buffer, followed by several rounds of centrifugation at a speed of 14-16,000 x g. The flow-through was
discarded following each wash and centrifugation. The process ends with step four, RNA elution. RNase-free water
was added to the center of the filter tube and allowed to sit and absorb for approximately two minutes before being
centrifuged. This final centrifugation left behind the purified RNA that would be converted to cDNA to be used for
qPCR.
2.11 RNA to cDNA Conversion
In order for a qPCR to be performed, RNA must be converted to cDNA. Three microliters of template RNA, two
microliters of mixed primers, four microliters of master buffer, and 11 microliters of distilled water were combined and
put into the PCR machine so that the RNA would be converted to cDNA. The exact protocol used can be found in
Figure 2.
2.12 qPCR
The qPCR, or quantitative polymerase chain reaction, is commonly used in laboratories to quantify gene expression in
a particular sample (Adamski 2014). Each qPCR required the use of a master mix. The master mix contained SYBR
green, ROX reference, distilled water, and the forward and reverse primer of each gene. The master mix was created
according to the Bimake™ 2x SYBR Green qPCR Master Mix protocol.
The same amounts of each component were used for each trial, as the concentrations of all of the cDNA samples used
were extremely similar. Because the samples were to be plated in triplicate, the master mix protocol was tripled. The
mixture was plated on a 96 well plate. To quantify and detect nucleic acids in the SKOV3 and CAOV3 cell lines. Five
trials of qPCR were performed in accordance with the Bimake™ 2x SYBR Green qPCR Master Mix protocol. Total
cellular RNA was isolated using RNeasy kit and 1ug of RNA was reverse transcribed to cDNA using the SuperScript
One Step RT-PCR system by Invitrogen, according to the manufacturer‟s instructions. cDNA at a 1:10 dilution was
used for all PCR reactions and primers were designed by Sigma (see primer sequences above). Each qPCR was
performed in triplicate to obtain the most accurate measurements possible, as errors could be made during the pipetting
process.
After the 96 well plate was loaded with the master mix and inserted into the qPCR machine, the temperature settings
were set based on the Bimake™ protocol. These temperature settings, along with the steps they coincide with, can be
found in Figure 3.1. All PCR reactions were performed on CFX-96 Bio-Rad RT System in and validated by the
presence of a single peak in the melt curve analysis. Changes in gene expression were calculated relative to the actin
and/or HPRT control.
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3. Results:
3.1 Cell Counting Kit-8
CCK-8 assays were performed using a 48-well plate. It was performed in triplicate in order to obtain accurate data. The
values for each treatment type obtained from the machine were averaged together to determine a mean cell viability
value. Cell viability was found to be highest in dual treated cells (mean: 0.42), and lowest in the carboplatin treated
cells (mean: 0.13). Figure XX illustrates the cell viability values for non-treated, carboplatin treated, cisplatin treated,
and dual treated SKOV3 cells.
3.2 Early Tox Live/Dead Analysis
To determine sensitivity of the cell lines to the various chemotherpay reagents, the EarlyTox live/dead assay was used.
As you can see from the results, treatment with either cisplatin (CIS+), carboplatin (CPT+), or dual (CIS+ and CPT+)
resulted in chemoresistance of SKOV3 as compared to the chemosensitive HOSE control population. CAOV3
exhibited a medial sensitivity.
3.3 Gel electrophoresis
After running the Gel electrophoresis on the two different DNA cell lines, SKOV3 and HOSE DNA, it was determined
that some of the primers were expressed in a particular cell line, while others were not. The ACT and SOX9 primers
were not expressed in either the chemoresistant cell line, SKOV3, or the chemosensitive cell line, HOSE. The FZD1
primer was expressed in both cell lines. POU5F1, NOTCH3, SLUG, GSK3b and ZEB1 were expressed in the
chemoresistant cell line but not in the sensitive cell line. Figure 4 outlines the expression levels of each primer tested in
SKOV3 and HOSE based upon the results of the gel electrophoresis experiments.
3.4 qPCR
After performing five qPCR trials, several cq values were obtained for each gene. These values were averaged together
to get a general representative cq value. A cq value above 32 indicates underexpression of the target gene, while a cq
value of below 28 indicates overexpression of the target gene. The results were graphed for facilitated visualization of
the data. Some cq values were not graphed, such as in the case of KLF4, as the results were inconclusive with values
ofboth over and underexpression. See Figure 7 and 8.

4. Discussion
Chemoresistance is a major cause of tumor recurrence and can potentially be attributed to cancer stem cells. The CCK8 assay performed in this study was used to determine the levels of SKOV3 cell viability and proliferation following
platinum-based chemotherapy treatment. Carboplatin and cisplatin are two major platinum-based chemotherapy drugs
used in the clinical setting. Based on the data collected from running the CCK-8 assay, it was found that carboplatin is
the most effective chemotherapeutic drug for treatment of chemoresistant cells of the SKOV3 cell line. The SKOV3
cells treated with carboplatin displayed the lowest levels of viability and proliferative ability. Cisplatin did not cause a
significant difference in cell viability and proliferation, as compared to the non-treated SKOV3 cells. While further
research is necessary to determine the most effective treatment, our study found that carboplatin had the greatest impact
on cell viability and proliferation of chemoresistant SKOV3 cells. This data could potentially be useful in the clinical
setting when treating ovarian cancer. The primary aim of this study was to identify the genes that are potentially
playing a role in the chemo resistance of ovarian cancer stem cells. These genes could be considered to be cancer stem
cell markers. The gel electrophoresis and PCR experiments performed following DNA extraction allowed for the
analysis of cancer stem cell gene expression. The extracted DNA from HOSE (Human Ovarian Surface Epithelial)
DNA and SKOV3 DNA were mixed with primers and then ran through a PCR machine for copying. Following the gel
electrophoresis, some of the primers were found to be expressed in the DNA while others were not. There are many
different reasons behind the minimal to no expression of the DNA in the gel, such that the primer/DNA is weak or the
PCR ran at a wrong frequency. HOSE cell line was the control cell line. SKOV3 cell line is the chemoresistant as it
resists the action of a chemical agent, however HOSE and A2780 are chemosensitive and are receptive to change to the
action of a chemical agent. Primers such as POU5F1, NOTCH3, SLUG, GSK3b, and ZEB1 were found to have
different expression levels in the chemoresistant SKOV3 cell line, as compared to the control HOSE cell line. These
results indicate that POU5F1, NOTCH3, SLUG, GSK3b, and ZEB1 expression was altered in chemoresistant ovarian
cancer stem cells and could therefore potentially be used as diagnostic markers. There is significance to the altered
expression of these specific genes in the chemoresistant SKOV3 cell line, as compared to HOSE. POU5F1 has
previously been found to be expressed in tumor initiating cells.
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Tumor initiating cells are responsible for tumor initiation, chemoresistance, and tumor metastasis (Wang 2015). In this
study, POU5F1 was found to be expressed only in the chemoresistant cell line. POU5F1 expression in chemoresistant
ovarian cancer cells could modulate the tumor initiation, metastasis, and lack of chemotherapeutic response. NOTCH 3
is widely known to play a role in apoptosis. Apoptosis, or programmed cell death, occurs as a result of DNA damage,
or when something goes wrong during the cell cycle. It is the body‟s way of ensuring that damaged cells will not
replicate. When apoptosis does not occur, damaged cells can replicate and cancer often results. Because NOTCH3
plays a role in apoptosis, altered NOTCH3 expression can lead to suppression of apoptosis, and therefore, cancer.
NOTCH3 expression was altered in SKOV3 cells, indicating that this gene is potentially allowing for tumor initiation.
SLUG, another gene with altered expression in SKOV3, has previously been linked to tumor progression (Ganesan
2016). Altered expression of a gene involved in tumor progression, such as SLUG, can potentially explain why cancer
stem cells metastasize effortlessly. GSK3b was found to also have altered expression in SKOV3. This gene in
particular plays various roles when considering cancer genetics. Some studies have found altered GSK3b expression is
involved in cancer progression and inhibition of apoptotic processes. Additionally, it is involved in oxidative stress
management within the cell. The inhibition of GSK3b helps maintain the stability of Nrf2, a transcription factor
necessary for defense against oxidative stress. Overexpression of GSK3b, therefore, leads to cellular oxidative stress
(Mancinelli 2017). Oxidative stress within a cell is associated with increased DNA damage, mutations, cancer cell
metastasis, and overall genomic instability (Reuter 2010). The results of this study indicate that GSK3b is likely
involved in cancer progression due to oxidative stress and apoptosis inhibition in ovarian cancer, as it was expressed in
only the chemoresistant cell line. ZEB1 is known in the scientific community to play a role in tumorigenicity. Studies
have shown that it is also linked to chemoresistance in breast cancer (Zhang 2018). Breast cancer is closely linked to
ovarian cancer when considering genetics. Being that ZEB1 has been found to be linked to chemoresistance in breast
cancer, it is likely that is also has this same role in ovarian cancer, especially when considering its altered expression in
the chemoresistant ovarian cancer cell line. It is evident that these genes plays a role in the progression of cancer, and
their altered expression in SKOV3 cells indicates that they are likely markers of chemoresistant ovarian cancer stem
cells.
Based on analysis of the data obtained from running five trials of qPCR, it was determined that three genes might have
a link to the chemoresistance of these cancer stem cells. The altered expression of GSK3b, CD34 and FZD1in the
resistant SKOV3 cell line lead to further analysis of the functions of these genes in order to determine why this might
be. As previously stated, overexpression of GSK3b leads to increased oxidative stress. According to the qPCR data,
this gene had altered expression in the chemoresistant SKOV3 cell line, as compared to the chemosensitive CAOV3
cell line. A gene such as GSK3b being overexpressed in a chemoresistant cell line could explain why the
chemoresistant ovarian cancer cells have an increased ability to proliferate, as the oxidative stress likely induced DNA
mutations. CD34 has previously been found to be overexpressed in response to cellular proliferation. Therefore, it has
been considered to be a marker of activated stem cells (Goodell 1999). Our qPCR data indicated that CD34 was, in
fact, overexpressed in the chemoresistant cell line, as compared to the chemosensitive cell line. It was expected for
CD34 to be overexpressed in the SKOV3 cell line, as cancer stem cells are proliferative cells. This data allows for
further confirmation of the status of CD34 as a cancer stem cell marker in ovarian cancer. FZD1 plays a crucial role in
multidrug chemoresistance. The Wnt/beta-catenin pathway regulates tumor proliferation, and FZD1 is a protein
involved in this pathway. Studies have shown that when FZD1 is overexpressed in breast cancer, multidrug
chemoresistance is the result (Zhang 2012). Breast cancer and ovarian cancer are closely linked genetically. Our data
indicated that FZD1 expression was altered in chemoresistant SKOV3 cells, as compared to chemosensitive CAOV3
cells. The altered expressed of FZD1 in the SKOV3 cell line could be responsible for its chemoresistant abilities.
The aforementioned genes can potentially be used as markers for diagnosis of ovarian cancer. Specifically, GSK3b is a
potential candidate for an ovarian cancer stem cell diagnostic marker, as its altered expression remained consistent in
both the gel electrophoresis and qPCR experiments. While the data collected from this study looks promising, more
trials need to be performed to confirm that this gene can be used as a diagnostic marker.
Additionally, more qPCR trials should also be performed using the same primers and cDNA samples to obtain more
accurate results. There is hope that with future research, the information gathered on this gene and its expression in
chemoresistant cell lines through this study can be brought into the clinical setting to diagnose and treat ovarian cancer.
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